Amy Chappell

Amy Chappell, M.D., FAAN, currently serves as Chief Medical Officer at Solaxa since January 2024 and holds positions as Neurology Advisor at Solaxa and Cleothena and Medical Consultant/Monitor at WuXi AppTec, both starting in October 2023. Additionally, Amy Chappell has been an Epilepsy Consultant at Avenue Therapeutics since November 2022 and a Strategic Advisor at Xalud Therapeutics, Inc. since April 2022. With a distinguished clinical scientist role at Sea Pharmaceuticals since January 2008 and serving as a Scientific Advisory Board Member at Pinteon Therapeutics since May 2020, Amy Chappell is also a Board Member at the American Society of Experiential Therapists, LLC since June 2016 and an Adjunct Clinical Associate Professor at Indiana University School of Medicine since May 2020. Educational credentials include a Bachelor of Science in Biology from Antioch College, an MD from Indiana University School of Medicine, and extensive residency training in neurology at Johns Hopkins Hospital. Moreover, participation in the Corporate Board Readiness Virtual Workshop Series in mid-2022 emphasizes ongoing professional development.